Patent Application
20200360326
The present invention relates to a stable aqueous liquid preparation containing a non-steroidal anti-inflammatory agent. In particular, the present invention relates to a stable aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof. More particularly, the present invention relates to an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a non-ionic surfactant.
Benzoylphenylacetic acid derivatives including bromfenac (generic name) of formula (I):
of which chemical name is 2-amino-3-(4-bromobenzoyl)phenylacetic acid are known as disclosed in JP-A-23052/1977 and its corresponding U.S. Pat. No. 4,045,576. 2-Amino-3-(4-bromobenzoyl)phenylacetic acid, its pharmacologically acceptable salt and a hydrate thereof are known as a non-steroidal anti-inflammatory agent, and they are effective against inflammatory diseases of anterior or posterior segment of the eye, such as blepharitis, conjunctivitis, scleritis, and postoperative inflammation in the field of ophthalmology, and its sodium salt has been practically used in the form of eye drops (“New Drugs in Japan, 2001”, 2001 Edition, Published by Yakuji Nippo Ltd., May 11, 2001, p. 27-29).
It was known that 2-amino-3-(4-bromobenzoyl)phenylacetic acid was unstable in aqueous formulations. Therefore, efforts were made to stabilize the eye drop mentioned above by means of addition of a water-soluble polymer (e.g., polyvinylpyrrolidone, polyvinyl alcohol, etc.) and a sulfite (e.g., sodium sulfite, potassium sulfite, etc.) (Japanese Patent No. 2,683,676 and its corresponding U.S. Pat. No. 4,910,225). Data were presented for only polyvinylpyrrolidone and polysorbate 80. It appeared that the formulations were stable when the pH was 8 or higher. However, even then, red precipitates were observed with formulations having polysorbate 80 after 3 weeks.
In addition, as an eye drop other than the above-mentioned one, Japanese Patent No. 2,954,356 (corresponding to U.S. Pat. Nos. 5,603,929 and 5,653,972) discloses an ophthalmic composition which comprises incorporating the antibacterial quaternary ammonium polymer Polyquad® (also known generically as polyquat-1) and boric acid into a formulation containing diclofenac as an acidic ophthalmic agent. Data was presented to show that the preservative efficacy of Polyquad® was maintained in one formulation. Although bromfenac was mentioned among the ophthalmic agents, no data was presented for any formulation containing that compound. The patentee there spoke of the stability of the formulations in term of the maintenance of the preservative efficacy. Nothing was disclosed regarding the physical or chemical stability of the active compound.
In Japanese Patent No. 2,954,356, there is the following description—“Benzalkonium chloride is a widely used preservative in ophthalmic solutions. However, benzalkonium chloride and other quaternary ammonium compounds are generally considered to be incompatible with ophthalmic compositions of drugs with acidic groups, such as nonsteroidal anti-inflammatory drugs. These preservatives lose their ability to function as they form complexes with the charged drug compounds.”
In these references, there is no disclosure or suggestion of, or the manner for, maintaining preservative efficacy and stability of the pharmaceutical active ingredient.
In general, the present invention provides a stable aqueous liquid composition, formulation, or preparation containing an acidic non-steroidal anti-inflammatory agent. An acidic non-steroidal anti-inflammatory agent is one that carries a carboxylic (i.e., —COOH) group. Throughout the present disclosure, the terms “composition,” “formulation,” and “preparation” are used interchangeably.
In one aspect, the present invention provides a stable aqueous liquid composition, formulation, or preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof. In the present disclosure, 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its salt or hydrate is also referred to, from time to time, as bromfenac.
In another aspect, the present invention provides an aqueous liquid composition, formulation, or preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a non-ionic surfactant.
In still another aspect, the present invention provides an aqueous liquid composition, formulation, or preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid (bromfenac) or a pharmacologically acceptable salt thereof or a hydrate thereof and a non-ionic surfactant, wherein at least 90 percent (alternatively, at least 92 or at least 94 percent) of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid remains in the composition upon storage at 60° C., for 4 weeks. In one embodiment, such storage is carried out in ambient humidity.
In yet another aspect, the present invention provides an aqueous liquid composition, formulation, or preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which is stable within a pH range giving no irritation to eyes and in which, when a preservative is incorporated therein, the preservative efficacy of the preservative does not substantially deteriorate upon storage.
In a further aspect, the present invention provides an aqueous liquid composition, formulation, or preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, the preservative efficacy of which is substantially maintained to satisfy the preservative efficacy acceptance criteria of US Pharmacopeia 35 (2012) or European Pharmacopeia 7th edition (201 2).
In another aspect, the invention provides a method for stabilizing an aqueous liquid composition, formulation, or preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof such that at least 90 percent (alternatively, 92 or at least 94 percent) of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid remains in the composition, formulation, or preparation upon storage at 60° C., for 4 weeks. In one embodiment, such storage is carried out in ambient humidity.
In still another aspect, the invention provides an aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt or hydrate thereof, and a preservative, wherein decrease in preservative efficacy of said preservative is inhibited.
As a result of various studies, the inventors of the present invention have found that, by adding certain non-ionic surfactant to an aqueous liquid composition containing a pharmaceutical active ingredient (“API”) of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, degradation of said API in said aqueous composition is inhibited.
In one aspect, at least 80 percent (alternatively, at least 82, at least 86, at least 90, at least 92, or at least 94 percent) of the original amount of said API remains in the composition after storage at 60° C., for 4 weeks. In one embodiment, such storage is carried out in ambient humidity.
In another aspect, at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said API remains in the composition after storage at 60 ° C., for 4 weeks. In one embodiment, such storage is carried out in ambient humidity.
In another aspect, an aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, and water. In one embodiment, the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxypropylene, fatty acid esters of polyethylene glycol, polyethylene glycol mono(alkylaryl) ethers, polyethoxylated triglycerides, polyethoxylated hydrogenated triglycerides, and mixtures thereof, and at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60° C., for 4 weeks.
In another aspect, an aqueous liquid preparation of the present invention does not include polysorbate 80.
In still another aspect, an aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, and water, wherein the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxypropylene, fatty acid esters of polyethylene glycol, polyethylene glycol mono(alkylaryl) ethers, polyethoxylated triglycerides, polyethoxylated hydrogenated triglycerides, and mixtures thereof.
In yet another aspect, an aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, water, and an ophthalmically acceptable preservative. In one embodiment, the non-ionic surfactant is a polyethylene glycol poly(alkylaryl) ether, and at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60° C., for 4 weeks.
In a further aspect, an aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, water, and benzalkonium chloride; wherein the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxypropylene, polyethylene glycol mono(alkylaryl) ethers, polyethoxylated triglycerides, and mixtures thereof; and wherein at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60° C., for 4 weeks.
In still another aspect, an aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, water, and an ophthalmically acceptable preservative; wherein the non-ionic surfactant is a polyethylene glycol poly(alkylaryl) ether; and wherein the ophthalmically acceptable preservative is selected from the group consisting of chlorhexidine, polyaminopropyl biguanide (“PAPB”), polyquaternium-1, polyquaternium-42, perborate, and mixtures thereof. In one embodiment, the polyethylene glycol poly(alkylaryl) ether is tyloxapol.
Non-limiting examples of non-ionic surfactants of the type of copolymers of polyoxyethylene and polyoxypropylene are known by their chemical names of αhydro-ω-hydroxypoly(oxyethylene)apoly(oxypropylene)bpoly(oxyethylene)ablock copolymer having formula of HO(CH2CH2O)a(CH2CH2CH2O)b(CH2CH2O)aH; wherein
Non-limiting examples of fatty acid esters of polyethylene glycol include esters of fatty acids having 8-24 carbon atoms (caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachic acid, behenic acid, lignoceric acid, oleic acid, linoleic acid, linolenic acid) and polyethylene glycol having 6-60 repeating units of —CH2CH2O—. In one embodiment, the mono-fatty acid ester of polyethylene glycol is polyoxyl 40 stearate.
Non-limiting examples of polyethylene glycol mono(alkylaryl) ethers include polyethylene nonylphenyl ethers (having common name of Nonoxynol or Nonoxinol; e.g., Nonoxinol 9, 11, and 11) and polyethylene glycol tetramethylbutylphenyl ethers (having common name of Octoxynol or Octoxinol; e.g., Octoxynol 9, 10, 16, 20, 30, and 40). In one embodiment, the polyethylene glycol mono(alkylaryl) ether is Octoxynol 40.
A non-limiting example of polyethylene glycol poly(alkylaryl) ether is tyloxapol, having Formula II.
Non-limiting examples of polyethoxylated triglycerides and polyethoxylated hydrogenated triglycerides include polyoxyl N castor oils (wherein N=30−40, such as polyoxyl 35 castor oil and polyoxyl 40 castor oil) and polyoxyl N hydrogenated castor oils (wherein N=4−60, such as polyoxyl 40 castor oil and polyoxyl 60 castor oil). In one embodiment, the non-ionic surfactant is polyoxy 40 castor oil.
As a result of various studies, the inventors of the present invention have found that, by adding a certain non-ionic surfactant such as one disclosed herein to an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, the aqueous solution becomes stable within a pH range, and change in the amount of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid over time can be inhibited. Further, when the aqueous solution contains a preservative, deterioration in the preservative effect of said preservative can be inhibited for a significant period of time, such as at least 28 days. In addition, the inventive preparation can reduce or avoid irritation to the eyes.
Namely, the present invention provides:
(1) An aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoly)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and a non-ionic surfactant.
(2) The aqueous liquid preparation according to the above (1), wherein the non-ionic surfactant is selected from the group consisting of poloxamer 407, polyoxyl 40 stearate, octoxynol 40, and polyethylene glycol 40 castor oil; and wherein when the non-ionic surfactant is polyoxyl 40 stearate, the liquid preparation excludes benzalkonium chloride.
(3) The aqueous liquid preparation according to the above (1) or (2), wherein the preparation further comprises a preservative selected from the group consisting of chlorhexidine, polyaminopropyl biguanide (“PAPB”), polyquaternium-1, polyquaternium-42, sodium perborate, and mixtures thereof.
(4) The aqueous liquid preparation according to the above (1), wherein the non-ionic surfactant is tyloxapol, and the preparation further comprises a preservative selected from the group consisting of chlorhexidine, polyaminopropyl biguanide (“PAPB”), polyquaternium-1, polyquaternium-42, sodium perborate, and mixtures thereof.
(5) The aqueous liquid preparation according to any one of the above (1) to (4), wherein the concentration of the non-ionic surfactant is in the range from 0.005 w/v % to 0.2 w/v %.
(6) The aqueous liquid preparation according to any one of the above (1) to (5), wherein the concentration of the non-ionic surfactant is in the range from 0.005 w/v % to 0.12 w/v %.
(7) The aqueous liquid preparation according to any one of the above (1) to (6), wherein the concentration of the non-ionic surfactant is in the range from 0.007 w/v % to 0.1 w/v %.
(8) The aqueous liquid preparation according to any one of the above (1) to (6), wherein the concentration of the non-ionic surfactant is in the range from 0.01 w/v % to 0.07 w/v %.
(9) The aqueous liquid preparation according to any one of the above (1) to (8), wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is 0.01 to 0.5 w/v %.
(10) The aqueous liquid preparation according to any one of the above (1) to (9), wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is 0.01 to 0.2 w/v %.
(11) The aqueous liquid preparation according to any one of the above (1) to (10), wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is 0.01 to 0.1 w/v %.
(12) The aqueous liquid preparation according to any one of the above (1) to (11), wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is 0.05 to 0.1 w/v %.
(13) The aqueous liquid preparation according to any one of the above (1) to (12), wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.
(14) The aqueous liquid preparation according to any one of the above (1) to (1 3), wherein the pH of the aqueous liquid preparation is within a range of 7 to 9.
(1 5) The aqueous liquid preparation according to the above (1) to (14), wherein the pH of the aqueous liquid preparation is within a range of 7.3 to 8.5.
(16) The aqueous liquid preparation according to the above (1) to (1 5), wherein the pH of the aqueous liquid preparation is within a range of 7.4 to 8.3.
(1 7) The aqueous liquid preparation according to any one of the above (1) to (16), wherein the aqueous liquid preparation is an eye drop.
(18) The aqueous liquid preparation according to any one of the above (1) to (16), wherein the aqueous liquid preparation is a nasal drop.
(19) An eye drop comprising sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate; a non-ionic surfactant at a concentration from 0.01 to 0.1 w/v %; and polyquaternium-1.
(20) An eye drop comprising: (a) 2-amino-3-(4-bromobenzoyl)phenylacetate, a salt thereof, or a hydrate thereof; (b) a non-ionic surfactant at a concentration from 0.01 to 0.1 w/v %; and (c) polyquaternium-1; wherein the eye drop satisfies acceptance criteria of the preservative efficacy test of US Pharmacopeia 35 (201 2).
(21) The liquid preparation of the above (1) or (2), further comprising a pharmaceutically acceptable preservative.
(22) The liquid preparation of the above (3) or (21), wherein the liquid preparation satisfies acceptance criteria of the preservative efficacy test of US Pharmacopeia 35 (2012).
(23) An eye drop comprising sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate, a non-ionic surfactant, and perborate; wherein the non-ionic surfactant is or consists of polyvinylpyrrolidone.
(24) The eye drop of the above (23), wherein the eye drop satisfies acceptance criteria of the preservative efficacy test of US Pharmacopeia 35 (2012).
(25) A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which method comprises incorporating a non-ionic surfactant into an aqueous liquid preparation comprising said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; wherein said stabilizing results in at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoly)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60° C., for 4 weeks.
(26) A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which method comprises incorporating a non-ionic surfactant into an aqueous liquid preparation comprising: (a) said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; and (b) a pharmaceutically acceptable preservative; wherein said stabilizing results in at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60° C., for 4 weeks.
(27) The method of the above (25) or (26); wherein the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxypropylene, fatty acid esters of polyethylene glycol, polyethylene glycol mono(alkylaryl) ethers, polyethoxylated triglycerides, polyethoxylated hydrogenated triglycerides, and mixtures thereof.
(28) The method of the above (26) or (27); wherein the preservative is selected from the group consisting of chlorhexidine, polyaminopropyl biguanide (“PAPB”), polyquaternium-1, polyquaternium-42, sodium perborate, and mixtures thereof.
(29) A method for inhibiting decrease in preservative efficacy of a preservative in an aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which method comprises incorporating a non-ionic surfactant into an aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative.
(30) The method of the above (29), wherein the preservative efficacy satisfies the preservative efficacy acceptance criteria of US Pharmacopeia 35 (2012).
(31) An invention, as recited in any one of the above (1) to (30), wherein the liquid preparation, composition, or formulation does not include any polyol.
(32) The invention of the above (31), wherein the polyol is mannitol.
(33) An aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant, water, and benzalkonium chloride; wherein the non-ionic surfactant is selected from the group consisting of copolymers of polyoxyethylene and polyoxypropylene, polyethylene glycol mono(alkylaryl) ethers, polyethoxylated triglycerides, and mixtures thereof; and wherein at least 90 percent (alternatively, at least 92 or at least 94 percent) of the original amount of said 2-amino-3-(4-bromobenzoyl)phenylacetic acid or pharmacologically acceptable salt thereof or hydrate thereof remains in the composition after storage at 60 ° C., for 4 weeks.
(34) An aqueous liquid composition of the present invention comprises 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, a non-ionic surfactant other than polysorbate 80, water, and perborate.
According to the present invention, a stable aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof can be prepared by incorporating a non-ionic surfactant, chosen from those disclosed in this disclosure, into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof. Also, an aqueous liquid preparation of the present invention, wherein a preservative is incorporated and has a sufficient preservative efficacy. In one embodiment, such preservative efficacy satisfies the acceptance criteria of US Pharmacopeia 35 (201 2).
Therefore, the aqueous liquid preparation of the present invention is advantageously used as an eye drop for the treatment of, for example, blepharitis, conjunctivitis, scleritis, and postoperative inflammation. In addition, such aqueous liquid preparation can be used as a nasal drop for the treatment of, for example, allergic rhinitis and inflammatory rhinitis (e.g., chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
The pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid includes, for example, an alkali metal salt such as sodium salt and potassium salt, and an alkaline earth metal salt such as calcium salt and magnesium salt, among which sodium salt is especially preferable.
2-Amino-3-(4-bromobenzoyl)phenylacetic acid and its pharmacologically acceptable salt can be prepared according to the method as described in JP-A-23052/1977 (corresponding to U.S. Pat. No. 4,045,576) or by a similar method thereof. These compounds can be obtained as their hydrate depending on synthetic conditions and recrystallization conditions. The hydrate includes 1/2 hydrate, 1 hydrate, and 3/2 hydrate, among which 3/2 hydrate is preferable.
In the aqueous liquid preparation of the present invention, the content (concentration range) of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is usually about 0.01 to 0.5 w/v %, or about 0.03 to 0.2 w/v %, or about 0.05 to 0.2 w/v %, or about 0.05 to 0.1 w/v %, or about 0.06 to about 0.1 w/v %. The concentration can appropriately vary to have any numerical value in said ranges, depending on the purpose of use and the degree of disease to be treated.
As used herein, the “alkyl” group can have a carbon number in the range from 1 to 18. For example, the alkyl group includes methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, 4-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 1,2-dimethylbutyl, 2-ethylbutyl, ethylbutyl, cyclopentyl, hexyl, cyclohexyl, heptyl, isoheptyl, octyl, isooctyl, nonyl, isononyl, decyl, isodecyl, undecyl, isoundecyl, dodecyl, isododecyl, tridecyl, isotridecyl, tetradecyl, isotetradecyl, pentadecyl, isopentadecyl, hexadecyl, isohexadecyl, heptadecyl, isoheptadecyl, octadecyl, isooctadecyl, and isomers thereof. For example, the octyl group includes isooctyl, sec-octyl, 1-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 1-propylpentyl, 1,5-dimethylhexyl, and 1,1,3,3-tetramethylbutyl.
As used herein, the “aryl” group includes one or more fused or bridged rings having a total carbon number from 5 to 14. Preferably, the aryl group is the phenyl group.
In some embodiments, the polyoxyethylene group can be represented by the formula O(CH2CH2O)xH in which x is an integer from 5 to 100, inclusive; such as 5 to 60, or 5 to 40, or 5 to 30.
Among the above-mentioned alkyl aryl polyether alcohol type polymers, tyloxapol having the following formula is preferable. Tyloxapol has Formula II, shown herein above.
The fatty acid of the polyethylene glycol fatty acid ester can be preferably a fatty acid having the carbon number of 8 to 24. Non-limiting examples of such polyethylene glycol fatty acid esters are polyethylene glycol monostearate (e.g. polyoxyl 8 stearate, polyoxyl 40 stearate, etc.), polyethylene glycol monolaurate, polyethylene glycol monooleate, polyethylene glycol diisostearate, polyethylene glycol dilaurate, polyethylene glycol dioleate, and the like. In some embodiments, polyethylene glycol monostearate or polyoxyl 40 stearate is used. Polyoxyl 40 stearate is an non-ionic surfactant and is a monostearic acid ester of an ethylene oxide condensed polymer. It can be represented by the formula C17H35COO(CH2CH2O)nH, wherein n is about 40.
Although the concentration range of the non-ionic surfactant in the aqueous liquid preparation of the present invention depends on the kind of compounds used, the minimum concentration is about 0.01 w/v % and the maximum concentration is about 0.5 w/v %. For example, the concentration range of a non-ionic surfactant can be from 0.01 w/v % to 0.05 w/v %, from 0.01 w/v % to 0.07 w/v, from 0.01 w/v % to 0.1 w/v %, from 0.01 w/v % to 0.12 w/v %, from 0.02 w/v % to 0.05 w/v %, from 0.02 w/v % to 0.07 w/v, from 0.02 w/v % to 0.1 w/v %, from 0.02 w/v % to 0.12 w/v %, from 0.03 w/v % to 0.05 w/v %, from 0.03 w/v % to 0.07 w/v, from 0.03 w/v % to 0.1 w/v %, or from 0.03 w/v % to 0.12 w/v %.
In some embodiments, when the non-ionic surfactant is tyloxapol, its concentration can be in the range from 0.01 w/v % to 0.05 w/v %, from 0.01 w/v % to 0.07 w/v, from 0.01 w/v % to 0.1 w/v %, from 0.01 w/v % to 0.12 w/v %, from 0.02 w/v % to 0.05 w/v %, from 0.02 w/v % to 0.07 w/v, from 0.02 w/v % to 0.1 w/v %, from 0.02 w/v % to 0.12 w/v %, from 0.03 w/v % to 0.05 w/v %, from 0.03 w/v % to 0.07 w/v, from 0.03 w/v % to 0.1 w/v %, or from 0.03 w/v % to 0.12 w/v %.
The incorporation ratio of a non-ionic surfactant in the aqueous liquid preparation of the invention is within a range from about 0.1 to about 0.5, from about 0.1 to about 1, or from about 0.5 to about 3, or from about 0.5 to about 5, or from about 0.2 to about 0.5, from about 0.2 to about 1, or from about 0.2 to about 3, or from about 0.3 to about 5, parts by weight relative to 1 part by weight of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof.
The preservative used in the present invention includes, for example, any preservative disclosed herein or equivalents thereof.
In some embodiments, when the preservative is polyquaternium-1 (also known as Polyquad®), a preparation, composition, or formulation of the present invention excludes polyols. In one aspect, such preparation, composition, or formulation can still satisfy the preservative efficacy acceptance criteria of US Pharmacopeia 35 (201 2).
Further, so long as the purpose of the present invention is achieved, various conventional additives such as tonicity-adjusting agents, buffers, thickeners, stabilizers, chelating agents, pH controlling agents, perfumes and the like may be appropriately added to the aqueous liquid preparation of the present invention. Non-limiting examples of tonicity-adjusting agents include sodium chloride, potassium chloride, monosaccharides (such as glucose), or disaccharides (such as sucrose). The buffers include, for example, phosphate buffer, borate buffer, citrate buffer, tartrate buffer, acetate buffer, boric acid, borax, amino acids, and the like. The thickeners include polyvinylpyrrolidone, carboxymethylcellulose, carboxypropylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, sodium polyacrylate, and the like. The stabilizers include sulfites such as sodium sulfite and the like. The chelating agents include sodium edetate, sodium citrate, sodium phosphate and the like. The pH controlling agents include hydrochloric acid, sodium hydroxide, phosphoric acid, acetic acid and the like. The perfumes include 1-menthol, borneol, camphor, Eucalyptus oil, and the like.
With respect to the concentrations of the above various additives in the aqueous liquid preparation of the present invention, a tonicity-adjusting agent may be included to achieve an osmolality in the range from about 230 to 350 mOsmol/kg (or from about 270 to about 320 mOsmol/kg).
The concentration of the buffering agent is chosen appropriately to achieve the desired pH, depending on the buffering agent. Such choice is within the skill of the art. For example, the buffering agent concentration can be in the range of 0.01 to 2 w/v %.
The concentration of a thickener to be added can be in the range from 0.1 to 10 w/v %, or from 0.1 to 3 w/v%, or from 0.1 to 1 w/v%.
The pH of the aqueous liquid preparation of the present invention is adjusted to about 6 to 9, or about 7 to 9, or about 7.3 to 8.5, or about 7.4 to 8.3.
So long as the purpose of the present invention is achieved, other kinds of active pharmaceutical ingredients may be appropriately added to treat or ameliorate additional conditions or disorders if such other active pharmaceutical ingredients are compatible with bromfenac or its pharmaceutically acceptable salts or esters (physically, chemically, and physiologically).
The aqueous liquid preparation of the present invention can be prepared by per se known method or according to the method as described in the Japanese Pharmacopoeia, 14th Edition, General Rules for Preparations, Solutions or Ophthalmic solutions.
For example, all desired ingredients at appropriate amounts (to achieve the final concentrations) may be added to a sterilized vessel, equipped with appropriate temperature control, internal atmosphere control, purging, and mixing implements. The ingredients may be added sequentially or together. The contents of the vessel are then mixed thoroughly until the contents are uniform. The contents are then packaged under sterility conditions into individual units.
The aqueous liquid preparation of the present invention can be applied to warm-blooded animals such as human, rat, mouse, rabbit, cow, pig, dog, cat, and the like.
The aqueous liquid preparation of the present invention can be prepared easily by dissolving the above-mentioned components in, for example, distilled water or sterile purified water. For example, the aqueous liquid preparation in the form of an eye drop can be used for the treatment of inflammatory diseases in anterior or posterior segment of the eye such as blepharitis, conjunctivitis, scleritis, postoperative inflammation, and the like. The dose of the aqueous liquid preparation containing 0.1 w/v % of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate is, for example, administered to an adult 3 to 6 times daily in an amount of 1 to 2 drops per one time. Depending on the degree of diseases, frequency of dosing is appropriately controlled.
The present invention is illustrated by way of non-limiting examples disclosed below.
Tables 1, 2, 3, 4, 5, and 6 present non-limiting exemplary compositions of the present invention. Tables 1 R, 2R, 3R, 4R, 5R, and 6R present the results of stability and preservative efficacy testing of these compositions.
Tables 1 R, 2R, 3R, 4R, and 5R show the remaining amount of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate after storage at 60° C. for 4 weeks as the percentage of the original amount of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate at the time of production. Correction for moisture vaporization from the container was also taken into account. As is apparent from these Tables, the remaining amount of sodium 2-amino-3-(4-bromobenzoyl)phenylacetate in these compositions indicate that bromfenac is surprisingly stable in a wide variety of compositions comprising various non-ionic surfactants and preservatives. These results indicate that these exemplary compositions or some variations thereof have good stability to be considered for use as pharmaceutical products, such as eye drops.
Preservative efficacy testing of these compositions was carried out against Staphylococcus aureus (hereinafter referred to as S. aureus), Escherichia Coli (hereinafter referred to as E. colt), Pseudomonas aeruginosa (hereinafter referred to as P. aeruginosa), Candida albicans (hereinafter referred to as C. albicans) and Aspergillus brasiliensis (hereinafter referred to as A. brasiliensis).
The results are shown in Tables 1 R, 2R, 3R, 4R, 5R, and 6R.
The EP-criteria A and EP-criteria B for preservative efficacy are given in the following.
Viable cell counts of bacteria (S. aureus, P. aeruginosa) 6 hours, 24 hours, and 28 days after inoculation decrease to not more than 1/100, not more than 1/1000, and undetectable, respectively.
Viable cell count of fungi (C. albicans, A. brasiliensis) 7 days after inoculation decreases to not more than 1/100, and thereafter, the cell count levels off or decreases.
Viable cell counts of bacteria (S. aureus, P. aeruginosa) at 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell counts level off or decrease.
Viable cell counts of fungi (C. albicans, A. brasiliensis) at 14 days after inoculation decrease to not more than 1/10, and thereafter, the cell counts keep the same level as that of 14 days after inoculation.
The USP (2012) criteria for ophthalmic products are given in the following.
Viable cell counts of bacteria (E. coli, S. aureus, P. aeruginosa) decrease to not more than 1/10 (of the initial counts) at 7 days after initial inoculation, not more than 1/1000 (of the initial counts) at 14 days after the initial inoculation, and at 28 days do not increase from the 14 days' cell counts.
Viable cell counts of fungi (C. albicans, A. brasiliensis) do not increase from the initial calculated cell counts at 7, 14, and 28 days after the initial inoculation.
aPerborate generates a low concentration of hydrogen peroxide that requires phosphonates for stability
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 1 shows compositions within the scope of the present invention comprising the non-ionic surfactant tyloxapol and exemplary preservatives other than benzalkonium chloride (“BAK”): polyquat-1, polyquat-42, perborate/Dequest® 2060, polyaminopropyl biguanide, and chlorhexidine. The chemical stability is judged from the remaining amount of bromfenac in the formulation after storage at 60° C. for 4 weeks (an aggressive stability testing) under ambient humidity. Stability results are shown in Table 1 R.
The results show stability of bromfenac for all preservatives tested, at least as good as, if not better than, the formulation with BAK. Compare with data disclosed in U.S. Pat. No. 8,129,431. Here, loss of bromfenac is in the range of 3-5%, with chlorhexidine showing the highest amount of loss of bromfenac (5%).
The compositions that include polyquatrenium-1 or polyquaternium-42 satisfy all three preservative efficacy criteria. The composition that includes PAPB satisfies the preservative efficacy criteria of EP-B and USP. The composition that includes sodium perborate/Dequest 2060 satisfies the preservative efficacy criteria USP.
Polyoxyl 40
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 2 shows compositions within the scope of the present invention, comprising a variety of exemplary non-ionic surfactants other than tyloxapol: Poloxamer 407, polyoxyl 40 stearate, Octoxynol 40, and PEG-40 castor oil. Stability results are shown in Table 2R. The results show stability of bromfenac for these surfactants, comparable to tyloxapol. Compare with data on tyloxapol in US Patent 8,129,431. Here, loss of bromfenac is in the range of 5-6% with Poloxamer 407, Octoxynol 40, and PEG-40 castor oil. Loss of bromfenac of 12% with polyoxyl 40 stearate was due to a high concentration of this surfactant, which was chosen for the test formulation. However, better bromfenac stability (comparable to that in formulation containing tyloxapol) may be achieved with lower concentrations of polyoxyl 40 stearate. Formulations NGB-6, NGB-8, and NGB-9 satisfy all three preservative efficacy criteria.
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 3 shows compositions within the scope of the present invention, comprising the preservative polyquat-1 (instead of BAK) and surfactants other than tyloxapol (Poloxamer 407, polyoxyl 40 stearate, Octoxynol 40, PEG-40 castor oil, and polysorbate 80). Stability results are shown in Table 3R. The results show stability of bromfenac in formulations containing polyquat-1 and Poloxamer 407, Octoxynol 40, or PEG-40 castor oil. The stability for these formulations is comparable to that containing BAK and tyloxapol. Compare with data on tyloxapol in U.S. Pat. No. 8,129,431. Here, loss of bromfenac is in the range of 5-7% with Poloxamer 407, Octoxynol 40, and PEG-40 castor oil. Loss of bromfenac of 13% with polyoxyl 40 stearate may be due to a high concentration of this surfactant, which was chosen for the test formulation. However, better bromfenac stability (comparable to that in formulation containing tyloxapol) may be achieved with lower concentrations of polyoxyl 40 stearate. A higher bromfenac loss with polysorbate 80 is consistent with previous findings disclosed in the '431 Patent.
These results show that the combinations of polyquat-1 and other selected surfactants are novel and non-obvious alternatives to the combination of BAK and tyloxapol. It is surprising that these formulations, which do not include any polyol, satisfy all three preservative efficacy criteria with only the polyquaternium-1 preservative.
Polyoxyl 40
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 4 shows a claimed formulation with the preservative PAPB (instead of BAK) and surfactants other than tyloxapol (Poloxamer 407, polyoxyl 40 stearate, Octoxynol 40, PEG-40 castor oil, and polysorbate 80). Stability results are shown in Table 4R.
Surprisingly, the results show good-to-excellent stability of bromfenac in formulations containing PAPB and these surfactants, even for polyoxyl 40 stearate at high concentration and polysorbate 80. These findings are non-obvious to persons skilled in the art, and patentable.
The stability for these formulations is better than for the formulation containing BAK and tyloxapol. Compare with data on tyloxapol in U.S. Pat. No. 8,129,431. Here, loss of bromfenac is in the range of 2-4% with Poloxamer 407, Octoxynol 40, PEG-40 castor oil, and polysorbate 80. Loss of bromfenac is higher, at 6-7% with polyoxyl 40 stearate. However, this result may be due to the high concentration of polyoxyl 40 stearate used in this formulation. Better bromfenac stability (comparable to that in formulation containing tyloxapol) may be achieved with lower concentrations of polyoxyl 40 stearate.
These results show that the combinations of the preservative PAPB and the selected nonionic surfactants are novel and non-obvious embodiments over the combination of BAK and tyloxapol. At the very low PAPB concentration of 0.0001% w/v, these formulations can satisfy the USP preservative efficacy criteria.
aPerborate generates a low concentration of hydrogen peroxide that requires phosphonates for stability
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 5 shows a claimed formulation with the preservative combination of perborate (instead of BAK) and the chelating agent Dequest® 2060, and surfactants other than tyloxapol (Poloxamer 407, polyoxyl 40 stearate, Octoxynol 40, PEG-40 castor oil, and polysorbate 80).
Stability results are shown in Table 5R.
Stability of bromfenac in formulations containing perborate/Dequest® 2060 and Poloxamer 407, Octoxynol 40, or PEG-40 castor oil is even somewhat better than for the formulation containing BAK and tyloxapol. Compare with data on tyloxapol in U.S. Pat. No. 8,129,431. Here, loss of bromfenac is in the range of 4-8% with Poloxamer 407, Octoxynol 40, and PEG-40 castor oil. Loss of bromfenac is higher, at 14-15% with polyoxyl 40 stearate. However, this result may be due to the high concentration of polyoxyl 40 stearate used in this formulation. Better bromfenac stability (comparable to that in formulation containing tyloxapol) may be achieved with lower concentrations of polyoxyl 40 stearate.
Loss of bromfenac is 1 3-14% with polysorbate 80. This is consistent with the results of benzalkonium chloride (“BAK”)/polysorbate 80 disclosed in the '431 Patent. In addition, it is suspected that polysorbate 80 (having a saccharide moiety) may be readily degraded by an oxidizing agent like perborate.
Table 5R (experiment NGB-25) shows that without polysorbate 80, the stability of bromfenac in the formulation containing perborate (bromfenac loss of 5-6%) is surprisingly even somewhat better than that in the formulation containing BAK/tyloxapol.
These results show that the combinations of the preservative perborate/chelating agent (such as Dequest® 2060) and Poloxamer 407, Octoxynol 40, or PEG-40 castor oil are novel and non-obvious over the combination of BAK and tyloxapol. At a low concentration of 0.02%w/v of sodium perborate, these formulations can satisfy the USP preservative efficacy criteria.
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
A. brasiliensis
C. Albicans
E. coli
S. aureus
P. aeruginosa
Table 6 shows some formulations comprising diclofenac (an non-steroidal anti-inflammatory agent) and polyquaternium-1 within the scope of the present invention and compared these formulations to those shown in U.S. Pat. No. 5,603,929 (issued to Desai). Table 6R shows the preservative efficacy results of the formulations shown in Table 6. Table 6R shows the log reduction in the counts of the microorganisms compared to the initial counts.
The following table (from Desai, U.S. Pat. No. 5,603,929) shows the criteria to pass the preservative efficacy testing under US Pharmacopeia XXII (“USP XXII”), European Pharmacopeia A (“EP-A”), and European Pharmacopeia B (“EP-B”) as existing at the time of Desai's disclosure. EP-A has the most stringent criteria.
DBP-1 is Desai's formulation B or C with diclofenac as the active ingredient. The concentration of polyquat-1 of 0.005% is what typically is used with this preservative. Note that Formulation A has the much higher concentration of 4% polyquat-1, a level of greater than 1000 times that typically used in commercial ophthalmic products. The experiments at 0.005% polyquat-1 show the importance of mannitol in achieving Desai's purpose.
DBP-2 is the same as DBP-1, except pH of 7.8, to discern any effect of pH.
DBP-3 and DBP-4 correspond to DBP-1 and DBP-2, respectively, without mannitol. The results for these formulations are to show the requirement of mannitol in Desai's formulation.
DBP-5 and DBP-6 correspond to DBP-1 and DBP-2, respectively, without mannitol, but with tyloxapol. Tyloxapol is not a polyol (instead, it is a polyether having Formula II shown above and is within the scope of the present invention).
Generally, everything else being kept constant, a lower pH of 7.4 is more effective than a pH of 7.8. However, whether a formulation meets the stated preservative efficacy criteria does not depend on pH in the range of 7.4-7.8.
Only formulations containing polyquat-1, boric acid, and mannitol (DBP-1 and DBP-2) meet all three preservative efficacy criteria, as they existed at the time of Desai's disclosure.
None of the formulations without mannitol (DBP-3 through DBP-6) meets any preservative efficacy criteria, as they existed at the time of Desai's disclosure because the population of the fungus A. brasiliensis shows an increase from the previous time point. Specifically, these formulations do not meet the USP XXII and EP-B criteria because the population of A. brasilliensis at 28 days is higher than that at 14 days. They do not meet the EP-A criteria because the population of A. brasiliensis at 28 days is higher than that at 7 days. In other words, excluding mannitol from Desai's formulations renders the latter unsuitable for their purpose; i.e., meeting both USP XXII and EP preservative efficacy criteria.
Nothing in Desai's disclosure suggests that a composition with polyquat-1 and without a polyol such as mannitol that is within the scope of the present invention would meet at least the USP preservative efficacy criteria at the time of the present invention.
Therefore, compositions within the scope of the present invention are novel and inventive over Desai's composition.
The aqueous liquid preparations of the present invention in the form of eye drops are useful for the treatment of ocular inflammation having diverse etiology, including blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Such preparations are also useful as nasal drop for the treatment of, for example, allergic rhinitis and inflammatory rhinitis (e.g., chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.)
While specific embodiments of the present invention have been described in the foregoing, it will be appreciated by those skilled in the art that many equivalents, modifications, substitutions, and variations may be made thereto without departing from the spirit and scope of the invention as defined in the appended claims.
| Number | Date | Country | |
|---|---|---|---|
| 61727940 | Nov 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14082662 | Nov 2013 | US |
| Child | 16983267 | US |
